Cadila Healthcare has entered into partnership with Medicure to launch cholesterol drug in the US market.

The company has entered into a definitive agreement with Medicure International Inc, a subsidiary of Medicure Inc. to commercialize its 505(b)(2) new drug application (NDA) product, pitavastatin magnesium (ZYPITAMAG) in the United States. ZYPITAMAG’s launch, marks the first branded product launch for Zydus in the US.

Further, under the agreement Zydus will hold the NDA and Medicure will be responsible for the sales and marketing of ZYPITAMAG.

Read EquityPandit’s Technical Analysis of Nifty Pharma Outlook for the Week